Keryx rated at buy by Jefferies

Keryx Biopharmaceuticals, Inc. was given a buy rating by Jefferies & Co., Inc. analyst Adam Walsh on positive Zerenex P2 data. The analyst believes in the large market potential of the product, complementary to Sulonex for diabetic nephropathy. Shares of the New York City-based development-stage company were up 55 cents, or 4.03%, at $14.20 on volume of 2,495,969 shares versus the three-month running average of 358,642 shares. (Nasdaq: KERX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.